Nevertheless, a systematic examination of ATR inhibitors and combinations with chemotherapy or PARP inhibitors specifically in pancreatic cancer patients with ATM mutations has not been performed and needs to be investigated prospectively in a clinical trial. The gene discussed is ATR; the disease is familial pancreatic carcinoma.